As we have discussed in previous posts, studies have shown that the hormones contained in the birth control product NuvaRing® have been linked to various forms of severe side-effects including: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage, myocardial infarction and pulmonary embolism.
Judge Rodney W.…
The latest financial statements from Merck, the manufacturer of the NuvaRing, appear to show that the warnings and surrounding litigation are slowing the drug’s use. According to a report on DrugRisk, an online pharmaceutical resource center, sales slipped by 2% from 2011. The drop is not surprising. Additionally, the New England Journal of Medicine and…
The British Medical Journal published a study from Denmark on May 10, 2012, linking vaginal rings like NuvaRing to as much as a 90% increased risk of blood clots over oral contraceptives. On June 14, 2012, the New England Journal of Medicine also published a Danish study finding vaginal ring contraceptives could relate to a…
As we have discussed in previous posts, studies have allegedly shown that the hormones contained in the birth control product NuvaRing® may be linked to various forms of severe side-effects including: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage, myocardial infarction and pulmonary embolism.
As we…
On August 1, 2012, the New Jersey Superior Court, Appellate Division upheld a state court’s dismissal of a Nuvaring lawsuit for failure to file the suit within the statute of limitations. Although the timeframe varies based on the state and the cause of action, a statute of limitations is the maximum length of time after…
Defendants in the NuvaRing® litigation recently filed a motion before Judge Martinotti, who is overseeing the New Jersey state cases, asking the Judge to compel Plaintiffs’ counsel to produce any documents related to two (2) experts retained in another mass tort, Yaz/Yasmin litigation. Defendants contend that Plaintiffs’ counsel had access to pre-publication information about new…
At a Case Management Conference on February 27, 2012, Judge Martinotti, who is overseeing all New Jersey state cases in the Nuvaring litigation, scheduled the first trial to begin on February 4, 2013. The parties expect the trial to last approximately one month, given the Court’s schedule and various holidays. At this point, it is…
As we have previously reported, Nuvaring, manufactured by Organon USA, was initially marketed in the United States in July 2002, after receiving FDA approval in late 2001. However, studies have shown that the ingredients contained in the birth control product NuvaRing may be linked to various forms of severe side-effects such as: heart attack,…
The Hon. Rodney W. Sippel, U.S.D.J., presides over the federal multi-district litigation in the Eastern District of Missouri addressing claims against NuvaRing®. Judge Sippel held a case management conference on February 14, 2011 at 3:30 p.m. wherein Plaintiffs addressed the possibility of naming an additional defendant, NV Organon. Judge Sippel Ordered Defendants to respond to Plaintiffs’ stipulation by March 16, 2011.
…
Continue Reading Possible New Defendant in NuvaRing® Mass Tort Litigation
As we have discussed in previous posts, studies have shown that the ingredients contained in the birth control product NuvaRing® have been linked to various forms of severe side-effects including: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage, myocardial infarction and pulmonary embolism.
…
Continue Reading Discovery For The Phase 1 Bellwether NuvaRing® Cases Have Been Scheduled
